Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Squamous Non-small Cell Lung Cancer × durvalumab × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 143 Lung Neoplasms 68 Small Cell Lung Carcinoma 50 Melanoma 8 Neoplasms 7 Carcinoma, Renal Cell 7 Squamous Cell Carcinoma of Head and Neck 6 Mesothelioma, Malignant 6 Mesothelioma 6 Carcinoma 6 Breast Neoplasms 6 Stomach Neoplasms 5 Neoplasm Metastasis 5 Colorectal Neoplasms 5 Carcinoma, Hepatocellular 5 Triple Negative Breast Neoplasms 4 Respiratory Tract Neoplasms 4 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Neoplasms by Site 4 Uterine Cervical Neoplasms 3 Urinary Bladder Neoplasms 3 Thoracic Neoplasms 3 Respiratory Tract Diseases 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Esophageal Neoplasms 3 Carcinoma, Merkel Cell 3 Carcinoma, Bronchogenic 3 Bronchial Neoplasms 3 Adenocarcinoma of Lung 3

Interventions

Paclitaxel 2 Carboplatin 2 tremelimumab 1 pembrolizumab 1 necitumumab 1 envafolimab 1 durvalumab 1 Nivolumab 1 Gemcitabine 1 Endostatins 1 Drug Therapy 1 Cisplatin 1 Afatinib 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03319316 2022-01-10

SOLUTION

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡